Laboratory of Extracellular Matrix Regeneration, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Schwerzenbach CH-8603, Switzerland.
Insilico Medicine US Inc., 345 Park Avenue South, 2nd Floor Suite 006, New York, NY 10010, USA.
Trends Pharmacol Sci. 2024 Jun;45(6):478-489. doi: 10.1016/j.tips.2024.04.010. Epub 2024 May 21.
Traf2- and Nck-interacting kinase (TNIK) has emerged as a key regulator of pathological metabolic signaling in several diseases and is a promising drug target. Originally studied for its role in cell migration and proliferation, TNIK possesses several newly identified functions that drive the pathogenesis of multiple diseases. Specifically, we evaluate TNIK's newfound roles in cancer, metabolic disorders, and neuronal function. We emphasize the implications of TNIK signaling in metabolic signaling and evaluate the translational potential of these discoveries. We also highlight how TNIK's role in many biological processes converges upon several hallmarks of aging. We conclude by discussing the therapeutic landscape of TNIK-targeting drugs and the recent success of clinical trials targeting TNIK.
Traf2- 和 Nck-interacting kinase (TNIK) 已成为多种疾病中病理代谢信号的关键调节因子，是有前途的药物靶点。最初因其在细胞迁移和增殖中的作用而被研究，TNIK 具有几个新发现的功能，这些功能推动了多种疾病的发病机制。具体来说，我们评估了 TNIK 在癌症、代谢紊乱和神经元功能中的新作用。我们强调了 TNIK 信号在代谢信号中的意义，并评估了这些发现的转化潜力。我们还强调了 TNIK 在许多生物学过程中的作用如何集中在衰老的几个标志上。最后，我们讨论了 TNIK 靶向药物的治疗前景和最近针对 TNIK 的临床试验的成功。
